Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by A Yamaguchi
Total Records ( 3 ) for A Yamaguchi
  T Tominaga , I Kimijima , M Kimura , Y Takatsuka , S Takashima , Y Nomura , F Kasumi , A Yamaguchi , N Masuda , S Noguchi and N. Eshima

Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles.


The subjects were post-menopausal Japanese patients who had undergone surgery for early breast cancer. Toremifene or tamoxifen was administered for 2 years. Lipid levels were measured before and up to 24 months after initiation.


Compared with baseline, at 24 months, the toremifene group (n = 123) showed significantly decreased total cholesterol (P < 0.001) and low-density lipoprotein cholesterol levels (P < 0.001), and significantly increased high-density lipoprotein cholesterol levels (P < 0.001). Their triglyceride levels were not affected (P = 0.677). The tamoxifen group (n = 120) also showed significantly decreased total cholesterol (P < 0.001) and low-density lipoprotein cholesterol levels (P < 0.001); no significant changes occurred in high-density lipoprotein cholesterol (P = 0.297) or triglyceride levels (P = 0.120).


Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.

  R Saito , A Yamaguchi , S. I Saitoh , K Kuma and I. Imai

The subarctic Pacific is known to have east–west gradients in the oceanic environment and phytoplankton community. The western subarctic Pacific is characterized by low temperature and high chlorophyll a (Chl a) while the eastern region by high temperature and low Chl a. Although there is little information on the differences in the zooplankton community between the eastern and western subarctic Pacific, the gradients in the oceanographic environment and phytoplankton community may markedly affect the zooplankton community in this region. The aim of this study is to clarify east–west differences in the subarctic Pacific zooplankton community. Zooplankton were sampled at stations along the 165°E line (western subarctic Pacific from 41°30'N to 49°30'N) and 165°W line (eastern subarctic Pacific from 39°N to 53°30'N) using 335 and 100 µm mesh size Twin NORPAC net during the summers of 2003–2006. East–west differences in the zooplankton community were characterized as: (i) greater total zooplankton abundance in the west and (ii) larger body size of calanoid copepods of the same copepodid stage in the west. Differences in east–west zooplankton abundances are attributed to differences in the magnitude of primary production (high in the west) and the size of primary producers (large in the west). Larger body sizes of calanoid copepods in the west are attributed to the lower temperature. Thus, differences in zooplankton abundance and body size are concluded to be due to east–west gradients in the oceanographic environment and phytoplankton community.

Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility